<DOC>
	<DOCNO>NCT02298842</DOCNO>
	<brief_summary>Verify vitro platelet quality ( functional assay ) platelet collect Trima Accel System , Version 6.4 , dilute InterSol Solution , store five day meet FDA requirement .</brief_summary>
	<brief_title>In-Vitro Study Platelets Collected Trima Accel System Stored InterSol Solution</brief_title>
	<detailed_description>Platelets suspend platelet additive solution ( PAS ) collect transfuse Europe 20 year . These PAS solution outside United States ( US ) tie apheresis device ; however US , PAS solution traditionally link corresponding apheresis device . Currently US , two solution approve Food Drug Administration ( FDA ) PAS replacement 65 % plasma platelet component . Isoplate Solution approve use Trima AccelÂ® Automated Blood Collection System ( Trima Accel System ) InterSol Solution approve use Amicus Separator System . This study design provide blood center option use either Isoplate InterSol collect platelet use PAS . Terumo BCT pursue approval InterSol Solution combination Trima Accel System . This randomized , pair , prospective , open-label , multi-center study . Up 100 healthy adult subject enrol study ensure 60 paired evaluable data point across two Investigational Sites . Evaluable define two complete platelet product 100mL plasma meet protocol analysis exclusion criterion . The additional platelet donor account screen failure , incomplete procedure , protocol exclusion . Two unit platelet collect subject : one Test unit collect hyperconcentrated platelet product 100 mL concurrent plasma one Control unit platelet plasma collect accord standard procedure . The Test unit suspend 65 % Intersol/35 % plasma immediately collection ; Control unit maintain 100 % plasma . Eligible donor sign informed consent enrol . Randomization occur ratio 1:1 one follow Treatment Arms : Arm A : Collection one Test unit follow collection one Control unit Arm B : Collection one Control unit follow collection one Test unit The standard apheresis platelet unit collect Control arm mirror hyperconcentrated platelet unit Test arm term yield final concentration . SUBJECT PROCEDURES Screening perform within 30 day apheresis procedure combine first Apheresis Visit . The following evaluation perform : 1 . Informed consent obtain prior initiate study specific procedures 2 . Eligibility confirm 3 . Demographics ( age , gender , ethnic origin ) , height , weight 4 . Complete blood count ( CBC ) hemoglobin platelet count subject new Investigative Site historical hemoglobin and/or platelet count measurement Apheresis Visit The following procedure perform first second Apheresis Visits : 1 . Eligibility confirm 2 . Finger stick hemoglobin 3 . First apheresis procedure perform Subject return Site 6 8 day follow first apheresis collection second apheresis collection . This conclude subject 's participation . Apheresis procedure run accord instruction precaution describe commercially available Trima Accel Operator 's Manual use Version 6.4 . The Investigator designee perform venipuncture , monitor subject collection , assess provide intervention adverse effect , remove needle , dress puncture site monitor subject recovery . The following documented : 1 . Trima Procedure detail 2 . Adverse event 3 . Medications treat AEs 4 . Device deficiency</detailed_description>
	<criteria>Age 18 year age old Meet inclusion criterion define Investigational Site apheresis double platelet plasma collection Trima Accel System . These criterion base American Association Blood Banks ( AABB ) standard . Note : Subjects defer volunteer community donation travel restriction , piercings tattoo may participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy Adults</keyword>
</DOC>